Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Speciality European Pharma Limited
Inclusion Criteria
* Males over 18 with documented advanced or metastatic prostate cancer
Outcome measures
* Comparative castration rates one week after starting therapy
* Degree of testosterone surge in the first month of treatment.
* Maintenance of medical castration during one year of therapy.
* Comparison of the treatments on QTc prolongation
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven prostate cancer and not previously treated with hormones
Evidance of advanced disease or metastases
Life expentancy of at least 3 months
Normal serum testosterone levels
Written informed consent
You may not be if
Previous endocrine or cytoxic theapy for prostate cancer
Known tumour complication of prostate cancer which owuld require immediate treatment
Another malignancy other than basal cell cancer
History of significant drug hypersensitivity to either LHRH agonists or GnRH antagonists.
Congenital or acquired coagulation disorders contraindicating intramuscular injections
Pagets disease of the bone
QTcB \> 450 msec at Day - 14
Clareo Health | Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
